Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-23T23:34:50.126Z Has data issue: false hasContentIssue false

Chapter 18 - Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder

from Section 5 - Therapeutic Applications of Neuroimaging in Mood Disorders

Published online by Cambridge University Press:  12 January 2021

By
Sameer Jauhar
Edited by
Sudhakar Selvaraj ,
Paolo Brambilla  and
Jair C. Soares
Sudhakar Selvaraj
Affiliation:
UTHealth School of Medicine, USA
Paolo Brambilla
Affiliation:
Università degli Studi di Milano
Jair C. Soares
Affiliation:
UT Harris County Psychiatric Center, USA
Get access

Summary

There is a curious disparity between the body of literature linking the dopamine system to schizophrenia/psychosis and bipolar disorder. This is surprising, given the similarities between the tenets of the dopamine hypothesis and schizophrenia and some states observed in bipolar disorder.

In this chapter, the author will present the evidence for a link between changes in the dopamine system and facets of bipolar disorder, the use of antipsychotics in bipolar disorder, and the possible integration of this knowledge in studying antipsychotic response and the dopamine system in bipolar disorder.

Type
Chapter
Information
Mood Disorders
Brain Imaging and Therapeutic Implications
 , pp. 236 - 247
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schildkraut, JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry. 1965 November 1; 122(5): 509–522.Google Scholar
Ashok, AH, Marques, TAR, Jauhar, S, et al. The dopamine hypothesis of bipolar affective disorder: The state of the art and implications for treatment. Mol Psychiatry. 2017 May; 22(5): 666–679.CrossRefGoogle ScholarPubMed
Beyer, DKE, Freund, N. Animal models for bipolar disorder: From bedside to the cage. Int J Bipolar Disord [Internet]. 2017 October 13:Google Scholar
Mania-like behavior induced by disruption of CLOCK | PNAS [Internet]. [cited 2019 Jul 19]. Available from: www.pnas.org/content/104/15/6406.Google Scholar
Sidor, MM, Spencer, SM, Dzirasa, K, et al. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry. 2015 November; 20(11): 1406–1419.Google Scholar
Tye, KM, Mirzabekov, JJ, Warden, MR, et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature. 2013 January 24; 493(7433): 537–541.CrossRefGoogle ScholarPubMed
Young, JW, Cope, ZA, Romoli, B, et al. Mice with reduced DAT levels recreate seasonal-induced switching between states in bipolar disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2018; 43(8):1721–1731.Google Scholar
Murphy, DL, Brodie, HKH, Goodwin, FK, Bunney, WE. Regular induction of hypomania by L -dopa in “bipolar” manic-depressive patients. Nature. 1971 January; 229(5280): 135.Google Scholar
Vlissides, DN, Gill, D, Castelow, J. Bromocriptine-induced mania? Br Med J. 1978 February 25; 1(6111): 510–510.Google Scholar
Jacobs, D, Silverstone, T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med. 1986 May; 16(2): 323–329.CrossRefGoogle Scholar
McTavish, SF, McPherson, MH, Harmer, CJ, et al. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry J Ment Sci. 2001 October; 179: 356–360.Google Scholar
Anand, A, Darnell, A, Miller, HL, et al. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry. 1999 April 15; 45(8): 972–978.Google Scholar
Delay, J, Deniker, P. 38 cas de psychoses traites par la cure prolong&. et continue de 4560 RP. Ann Med Psychol. 1952; 110: 364–396.Google Scholar
Klein, DF, Oaks, G. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry. 1967 January 1; 16(1): 118–126.Google Scholar
Baldessarini, RJ, Tondo, L, Vázquez, GH. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry. 2019 February; 24(2): 198–217.Google Scholar
Cipriani, A, Barbui, C, Salanti, G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet Lond Engl. 2011 October 8; 378(9799): 1306–1315.CrossRefGoogle Scholar
Jauhar, S, Young, AH. Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. Int J Bipolar Disord. 2019 March 27; 7(1): 10.CrossRefGoogle ScholarPubMed
Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study | American Journal of Psychiatry [Internet]. [cited 2019 Jun 26].Google Scholar
Durgam, S, Earley, W, Lipschitz, A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016 March 1; 173(3): 271–281.Google Scholar
Young, AH, McElroy, SL, Bauer, M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010 February; 71(2): 150–62.Google Scholar
Veselinović, T, Paulzen, M, Gründer, G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother. 2013 November; 13(11): 1141–1159.CrossRefGoogle ScholarPubMed
Lindström, L, Lindström, E, Nilsson, M, Höistad, M. Maintenance therapy with second generation antipsychotics for bipolar disorder – A systematic review and meta-analysis. J Affect Disord. 2017; 15(213): 138–150.Google Scholar
Macfadden, W, Alphs, L, Haskins, JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009 December; 11(8): 827–839.CrossRefGoogle ScholarPubMed
Ketter, TA, Sarma, K, Silva, R, et al. Lurasidone in the long-term treatment of patients with bipolar disorder: A 24-week open-label extension study. Depress Anxiety. 2016 May 1; 33(5): 424–434.Google Scholar
Szegedi, A, Durgam, S, Mackle, M, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry. 2018 01; 175(1): 71–79.CrossRefGoogle ScholarPubMed
Calabrese, JR, Sanchez, R, Jin, N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: A double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. 2017; 78(3): 324–331.CrossRefGoogle ScholarPubMed
Quiroz, JA, Yatham, LN, Palumbo, JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010 July 15; 68(2): 156–162.Google Scholar
Vieta, E, Montgomery, S, Sulaiman, AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2012 November; 22(11): 825–835.Google Scholar
Kishi, T, Oya, K, Iwata, N. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: A systematic review and meta-analyses of randomized controlled trials. Int J Neuropsychopharmacol [Internet]. 2016 September 21; 19(9): pyw038. DOI:10.1093/ijnp/pyw038.Google Scholar
Paul, Cumming. Imaging Dopamine. Cambridge University Press; 2009.Google Scholar
Paul, Cumming. Imaging Dopamine. Cambridge University Press. 2009.Google Scholar
Wagner, HN, Burns, HD, Dannals, RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science. 1983 September 23; 221(4617): 1264–1266.Google Scholar
Nord, M, Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011 April 1; 17(2): 97–103.Google Scholar
Piccini, P, Pavese, N, Brooks, DJ. Endogenous dopamine release after pharmacological challenges in Parkinson’s disease. Ann Neurol. 2003 May; 53(5): 647–653.CrossRefGoogle ScholarPubMed
Cropley, VL, Fujita, M, Innis, RB, Nathan, PJ. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry. 2006 May 15; 59(10): 898–907.Google Scholar
Garnett, ES, Firnau, G, Nahmias, C. Dopamine visualized in the basal ganglia of living man. Nature. 1983 September 8; 305(5930): 137–138.CrossRefGoogle ScholarPubMed
Barrio, JR, Huang, SC, Yu, DC, et al. Radiofluorinated L-m-tyrosines: New in-vivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 1996 July; 16(4): 667–678.Google Scholar
DeJesus, OT, Murali, D, Kitchen, R, et al. Evaluation of 3-[18 F]fluoro-alpha-fluoromethyl-p-tyrosine as a tracer for striatal tyrosine hydroxylase activity. Nucl Med Biol. 1994 May; 21(4): 663–667.CrossRefGoogle ScholarPubMed
Innis, R, Baldwin, R, Sybirska, E, et al. Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]CIT. Eur J Pharmacol. 1991 August 6; 200(2–3): 369–370.CrossRefGoogle ScholarPubMed
Aquilonius, S-M, Bertröm, K, Eckernäs, S-Å, et al. In vivo evaluation of striatal dopamine reuptake sites using 11 C-nomifensine and positron emission tomography. Acta Neurol Scand. 1987 October 1; 76(4): 283–287.Google Scholar
Wong, DF, Yung, B, Dannals, RF, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11 C]WIN 35,428. Synapse. 1993 October 1; 15(2): 130–142.Google Scholar
Volkow, ND, Ding, YS, Fowler, JS, et al. A new PET ligand for the dopamine transporter: Studies in the human brain. J Nucl Med Off Publ Soc Nucl Med. 1995 December; 36(12): 2162–2168.Google Scholar
Mozley, PD, Stubbs, JB, Plössl, K, et al. Biodistribution and dosimetry of TRODAT-1: a technetium-99 m tropane for imaging dopamine transporters. J Nucl Med Off Publ Soc Nucl Med. 1998 December; 39(12): 2069–2076.Google Scholar
Halldin, C, Stone-Elander, S, Farde, L, et al. Preparation of 11 C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum [A]. 1986; 37(10): 1039–1043.CrossRefGoogle Scholar
Halldin, C, Foged, C, Chou, YH, et al. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med Off Publ Soc Nucl Med. 1998 December; 39(12): 2061–2068.Google ScholarPubMed
Sit, S-Y, Xie, K, Jacutin-Porte, S, et al. (+)-Dinapsoline: An efficient synthesis and pharmacological profile of a novel dopamine agonist. J Med Chem. 2002 August 1; 45(17): 3660–3668.Google Scholar
Leysen, JE, Gommeren, W, Laduron, PM. Spiperone: A ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol. 1978 February 1; 27(3): 307–316.Google Scholar
Köhler, C, Hall, H, Ogren, SO, Gawell, L. Specific in vitro and in vivo binding of 3 H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985 July 1; 34(13):2251–229.Google Scholar
Kung, HF, Pan, S, Kung, MP, et al. In vitro and in vivo evaluation of [123I]IBZM: A potential CNS D-2 dopamine receptor imaging agent. J Nucl Med Off Publ Soc Nucl Med. 1989 January; 30(1): 88–92.Google Scholar
Mukherjee, J, Christian, BT, Dunigan, KA, et al. Brain imaging of 18 F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synap N Y N. 2002 December 1; 46(3): 170–88.Google Scholar
Olsson, H, Halldin, C, Swahn, CG, Farde, L. Quantification of [11 C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 1999 October; 19(10): 1164–1173.Google Scholar
Seeman, P, Ko, F, Willeit, M, McCormick, P, Ginovart, N. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2high and D3high receptors. Synapse. 2005 November 1; 58(2): 122–128.Google Scholar
Hwang, DR, Kegeles, LS, Laruelle, M. (-)-N-[(11)C]propyl-norapomorphine: A positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol. 2000 August; 27(6): 533–539.Google Scholar
Finnema, SJ, Seneca, N, Farde, L, et al. A preliminary PET evaluation of the new dopamine D2 receptor agonist [11 C]MNPA in cynomolgus monkey. Nucl Med Biol. 2005 May; 32(4): 353–360.Google Scholar
Jauhar, S, Veronese, M, Rogdaki, M, et al. Regulation of dopaminergic function: An [18 F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry. 2017 February 7; 7(2): e1027.CrossRefGoogle ScholarPubMed
Narendran, R, Frankle, WG, Mason, NS, et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synap N Y N. 2009 June; 63(6): 447–461.Google Scholar
Shotbolt, P, Tziortzi, AC, Searle, GE, et al. Within-subject comparison of [11C]-(+)-PHNO and [11C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab. 2012 January; 32(1): 127–136.CrossRefGoogle ScholarPubMed
Cropley, VL, Fujita, M, Bara-Jimenez, W, et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res. 2008 July 15; 163(2): 171–82.Google Scholar
Hernaus, D, Mehta, MA. Prefrontal cortex dopamine release measured in vivo with positron emission tomography: Implications for the stimulant paradigm. NeuroImage. 2016 November 15; 142: 663–667.Google Scholar
Laruelle, Marc. Measuring dopamine synaptic transmission with molecular imaging and pharmacological challenges: The state of the art. In: Gründer, Gerhard, editors. Molecular Imaging in the Clinical Neurosciences. New York: Springer; 2012, pp. 163–203.Google Scholar
Zubieta, J-K, Huguelet, P, Ohl, LE, et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: Sex differences and cognitive correlates. Am J Psychiatry. 2000 October 1; 157(10): 1619–1628.Google Scholar
Yatham, LN, Liddle, PF, Shiah, I-S, et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: Effects of treatment with divalproex sodium. Am J Psychiatry. 2002 May; 159(5): 768–774.CrossRefGoogle Scholar
Jauhar, S, Nour, MM, Veronese, M, et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry. 2017 October 11; 74(12): 1206–1213.CrossRefGoogle ScholarPubMed
Anand, A, Verhoeff, P, Seneca, N, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000 July; 157(7): 1108–1114.Google Scholar
Anand, A, Barkay, G, Dzemidzic, M, et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011; 13(4): 406–413.CrossRefGoogle ScholarPubMed
Amsterdam, JD, Newberg, AB. A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology. 2007; 55(3–4): 167–170.Google Scholar
Chang, TT, Yeh, TL, Chiu, NT, et al. Higher striatal dopamine transporters in euthymic patients with bipolar disorder: A SPECT study with [99mTc] TRODAT-1. Bipolar Disord. 2010 February 1; 12(1): 102–106.Google Scholar
Yatham, LN, Liddle, PF, Lam, RW, et al. PET study of the effects of valproate on dopamine D2 receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry. 2002 October 1; 159(10): 1718–1723.Google Scholar
Suhara, T, Nakayama, K, Inoue, O, et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl). 1992; 106(1): 14–18.Google Scholar
Pearlson, GD, Wong, DF, Tune, LE, et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry. 1995 June; 52(6): 471–477.Google Scholar
Leung, K. 3-N-[11C]methylspiperone. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004 [cited 2019 July 20].Google Scholar
Jauhar, S, Howes, OD. Understanding and predicting variability in response to treatment in psychotic disorders: In vivo findings. Clin Pharmacol Ther. 2019 May; 105(5): 1079–1081.Google Scholar
Jauhar, S, Veronese, M, Nour, MM, et al. Determinants of treatment response in first-episode psychosis: An 18 F-DOPA PET study. Mol Psychiatry. 2019 October; 24(10): 1502–1512.Google Scholar
Jauhar, S, Ratheesh, A, Davey, C, et al. The case for improved care and provision of treatment for people with first-episode mania. Lancet Psychiatry [Internet]. 2019 October 01; 6(10): P869–876.Google Scholar
Egerton, A, Demjaha, A, McGuire, P, Mehta, MA, Howes, OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage. 2010 Apr 1;50(2):524–31.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×